# Celcuity

Celcuity is an Asset Manager based in Minneapolis, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Minneapolis, United States
- **Region:** North America
- **Address:** Minneapolis, MN, United States
- **Founded:** 2012
- **Assets under management:** Undisclosed
- **Website:** celcuity.com

## Regulatory record

- **Reports private funds:** No

## About

Celcuity is a clinical-stage biotechnology company founded in 2012 in Minneapolis, Minnesota. It focuses on developing therapies for cancer treatment. The company's lead candidate, gedatolisib, targets the PI3K/AKT/mTOR pathway as a pan-PI3K, mTOR inhibitor.

## Sectors

- Digital Health
- Healthcare Services

## People

- Brian Sullivan — Chairman and Chief Executive Officer

## Questions

### Who runs investment and strategic decisions at Celcuity?

Brian Sullivan serves as Chairman and CEO, leading the firm since its founding in 2012. He is responsible for capital allocation, corporate strategy, and the decision to in-license gedatolisib from Pfizer. The firm's publicly traded structure (Nasdaq: CELC) places ultimate strategic oversight with the board of directors and shareholders.

### What is the CELsignia platform and how does it differ from genomic testing?

CELsignia measures the functional activity of cellular signaling pathways in live tumor cells, providing a real-time view of whether pathways such as PI3K or MAPK are hyperactive. This contrasts with genomic sequencing, which identifies mutations but cannot confirm whether the associated pathway is functionally driving tumor growth. The technology was in-licensed from the Moffitt Cancer Center and the University of South Florida.

### What is the status of the VIKTORIA-1 clinical trial?

VIKTORIA-1 is a Phase 3 registrational trial evaluating gedatolisib in combination with fulvestrant, with or without palbociclib, in patients with HR+/HER2- advanced breast cancer. Celcuity announced the first patient dosed in February 2024. The trial is designed to support a regulatory submission for marketing approval if the endpoints are met.

### Where does Celcuity's underlying technology come from?

The foundational CELsignia technology was developed at the H. Lee Moffitt Cancer Center and the University of South Florida. Celcuity in-licensed the intellectual property and has built the commercial diagnostic platform and clinical trial infrastructure around it.

## Related profiles

- [Federal Signal](https://altss.com/profile/federal-signal-corp-de)

---

Last updated: 2026-05-30T17:29:53.186Z

Canonical page: https://altss.com/profile/celcuity-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology